(MSGS) Madison Square Garden Sports - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US55825T1034
Stock: Basketball Team, Hockey Team, G-League Affiliate, AHL Affiliate
Total Rating 48
Risk 35
Buy Signal -0.29
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 27.5% |
| Relative Tail Risk | -9.96% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.09 |
| Alpha | 22.08 |
| Character TTM | |
|---|---|
| Beta | 0.656 |
| Beta Downside | 0.930 |
| Drawdowns 3y | |
|---|---|
| Max DD | 25.54% |
| CAGR/Max DD | 0.57 |
Description: MSGS Madison Square Garden Sports January 08, 2026
Madison Square Garden Sports Corp. (MSGS) is a U.S.-based professional sports operator that owns the New York Knicks (NBA) and New York Rangers (NHL), along with their development-league affiliates-the Westchester Knicks (NBA G League) and Hartford Wolf Pack (AHL). The firm also runs the Madison Square Garden Training Center in Greenburgh, providing performance services to its teams. Incorporated in 2015 after splitting from The Madison Square Garden Company, MSGS is listed on NYSE under the ticker “MSGS.”
Key financial and industry drivers: in FY 2023 the company generated roughly $1.5 billion in revenue, with franchise operating income contributing about 70% of earnings; ticket-sale trends and media-rights agreements (e.g., the NBA’s $24 billion TV deal through 2025) are primary revenue levers. The sports-entertainment sector remains highly sensitive to consumer-discretionary spending cycles and macro-level wage growth, which influence attendance and sponsorship spend. Additionally, the salary-cap structure in both the NBA and NHL caps labor cost volatility, providing a relatively predictable expense framework.
For a deeper dive into MSGS’s valuation metrics and scenario analysis, consider checking ValueRay’s platform.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -23.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -6.51 > 1.0 |
| NWC/Revenue: -38.21% < 20% (prev -32.78%; Δ -5.43% < -1%) |
| CFO/TA 0.02 > 3% & CFO 32.8m > Net Income -23.7m |
| Current Ratio: 0.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (24.1m) vs 12m ago 0.28% < -2% |
| Gross Margin: 26.03% > 18% (prev 0.40%; Δ 2563 % > 0.5%) |
| Asset Turnover: 70.94% > 50% (prev 75.54%; Δ -4.60% > 0%) |
| Interest Coverage Ratio: 0.05 > 6 (EBITDA TTM 4.40m / Interest Expense TTM 21.2m) |
Altman Z'' -2.09
| A: -0.26 (Total Current Assets 245.5m - Total Current Liabilities 637.3m) / Total Assets 1.52b |
| B: -0.10 (Retained Earnings -146.4m / Total Assets 1.52b) |
| C: 0.00 (EBIT TTM 1.15m / Avg Total Assets 1.45b) |
| D: -0.08 (Book Value of Equity -147.1m / Total Liabilities 1.81b) |
| Altman-Z'' Score: -2.09 = D |
Beneish M -2.62
| DSRI: 0.93 (Receivables 74.2m/80.7m, Revenue 1.03b/1.04b) |
| GMI: 1.53 (GM 26.03% / 39.82%) |
| AQI: 1.05 (AQ_t 0.32 / AQ_t-1 0.30) |
| SGI: 0.99 (Revenue 1.03b / 1.04b) |
| TATA: -0.04 (NI -23.7m - CFO 32.8m) / TA 1.52b) |
| Beneish M-Score: -2.62 (Cap -4..+1) = A |
What is the price of MSGS shares?
As of February 07, 2026, the stock is trading at USD 279.29 with a total of 243,142 shares traded.
Over the past week, the price has changed by -1.50%, over one month by +10.37%, over three months by +29.50% and over the past year by +32.76%.
Over the past week, the price has changed by -1.50%, over one month by +10.37%, over three months by +29.50% and over the past year by +32.76%.
Is MSGS a buy, sell or hold?
Madison Square Garden Sports has received a consensus analysts rating of 4.13.
Therefore, it is recommended to buy MSGS.
- StrongBuy: 4
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MSGS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 280.5 | 0.4% |
| Analysts Target Price | 280.5 | 0.4% |
| ValueRay Target Price | 316.1 | 13.2% |
MSGS Fundamental Data Overview January 31, 2026
P/E Forward = 72.4638
P/S = 6.7023
P/B = 1.57
Revenue TTM = 1.03b USD
EBIT TTM = 1.15m USD
EBITDA TTM = 4.40m USD
Long Term Debt = 267.0m USD (from longTermDebt, last quarter)
Short Term Debt = 78.2m USD (from shortTermDebt, last quarter)
Debt = 1.17b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.12b USD (from netDebt column, last quarter)
Enterprise Value = 7.99b USD (6.87b + Debt 1.17b - CCE 57.3m)
Interest Coverage Ratio = 0.05 (Ebit TTM 1.15m / Interest Expense TTM 21.2m)
EV/FCF = 246.4x (Enterprise Value 7.99b / FCF TTM 32.4m)
FCF Yield = 0.41% (FCF TTM 32.4m / Enterprise Value 7.99b)
FCF Margin = 3.16% (FCF TTM 32.4m / Revenue TTM 1.03b)
Net Margin = -2.31% (Net Income TTM -23.7m / Revenue TTM 1.03b)
Gross Margin = 26.03% ((Revenue TTM 1.03b - Cost of Revenue TTM 758.4m) / Revenue TTM)
Gross Margin QoQ = 76.96% (prev 23.69%)
Tobins Q-Ratio = 5.27 (Enterprise Value 7.99b / Total Assets 1.52b)
Interest Expense / Debt = 0.48% (Interest Expense 5.59m / Debt 1.17b)
Taxrate = 21.0% (US default 21%)
NOPAT = 910.9k (EBIT 1.15m * (1 - 21.00%))
Current Ratio = 0.39 (Total Current Assets 245.5m / Total Current Liabilities 637.3m)
Debt / Equity = -3.99 (negative equity) (Debt 1.17b / totalStockholderEquity, last quarter -294.2m)
Debt / EBITDA = 253.9 (Net Debt 1.12b / EBITDA 4.40m)
Debt / FCF = 34.46 (Net Debt 1.12b / FCF TTM 32.4m)
Total Stockholder Equity = -283.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.64% (Net Income -23.7m / Total Assets 1.52b)
RoE = 8.37% (negative equity) (Net Income TTM -23.7m / Total Stockholder Equity -283.1m)
RoCE = -7.18% (negative capital employed) (EBIT 1.15m / Capital Employed (Equity -283.1m + L.T.Debt 267.0m))
RoIC = 7.96% (NOPAT 910.9k / Invested Capital 11.4m)
WACC = 7.17% (E(6.87b)/V(8.05b) * Re(8.33%) + D(1.17b)/V(8.05b) * Rd(0.48%) * (1-Tc(0.21)))
Discount Rate = 8.33% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.11%
[DCF Debug] Terminal Value 80.49% ; FCFF base≈66.9m ; Y1≈63.3m ; Y5≈60.0m
Fair Price DCF = 7.85 (EV 1.27b - Net Debt 1.12b = Equity 153.4m / Shares 19.5m; r=7.17% [WACC]; 5y FCF grow -6.99% → 2.90% )
EPS Correlation: -38.04 | EPS CAGR: -18.65% | SUE: -0.52 | # QB: 0
Revenue Correlation: -8.32 | Revenue CAGR: -41.23% | SUE: -0.09 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.46 | Chg30d=-0.837 | Revisions Net=+1 | Analysts=4
EPS current Year (2026-06-30): EPS=-0.48 | Chg30d=+0.642 | Revisions Net=-2 | Growth EPS=+47.9% | Growth Revenue=-3.6%
EPS next Year (2027-06-30): EPS=-0.28 | Chg30d=-0.119 | Revisions Net=-1 | Growth EPS=+41.8% | Growth Revenue=+4.6%
P/S = 6.7023
P/B = 1.57
Revenue TTM = 1.03b USD
EBIT TTM = 1.15m USD
EBITDA TTM = 4.40m USD
Long Term Debt = 267.0m USD (from longTermDebt, last quarter)
Short Term Debt = 78.2m USD (from shortTermDebt, last quarter)
Debt = 1.17b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.12b USD (from netDebt column, last quarter)
Enterprise Value = 7.99b USD (6.87b + Debt 1.17b - CCE 57.3m)
Interest Coverage Ratio = 0.05 (Ebit TTM 1.15m / Interest Expense TTM 21.2m)
EV/FCF = 246.4x (Enterprise Value 7.99b / FCF TTM 32.4m)
FCF Yield = 0.41% (FCF TTM 32.4m / Enterprise Value 7.99b)
FCF Margin = 3.16% (FCF TTM 32.4m / Revenue TTM 1.03b)
Net Margin = -2.31% (Net Income TTM -23.7m / Revenue TTM 1.03b)
Gross Margin = 26.03% ((Revenue TTM 1.03b - Cost of Revenue TTM 758.4m) / Revenue TTM)
Gross Margin QoQ = 76.96% (prev 23.69%)
Tobins Q-Ratio = 5.27 (Enterprise Value 7.99b / Total Assets 1.52b)
Interest Expense / Debt = 0.48% (Interest Expense 5.59m / Debt 1.17b)
Taxrate = 21.0% (US default 21%)
NOPAT = 910.9k (EBIT 1.15m * (1 - 21.00%))
Current Ratio = 0.39 (Total Current Assets 245.5m / Total Current Liabilities 637.3m)
Debt / Equity = -3.99 (negative equity) (Debt 1.17b / totalStockholderEquity, last quarter -294.2m)
Debt / EBITDA = 253.9 (Net Debt 1.12b / EBITDA 4.40m)
Debt / FCF = 34.46 (Net Debt 1.12b / FCF TTM 32.4m)
Total Stockholder Equity = -283.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.64% (Net Income -23.7m / Total Assets 1.52b)
RoE = 8.37% (negative equity) (Net Income TTM -23.7m / Total Stockholder Equity -283.1m)
RoCE = -7.18% (negative capital employed) (EBIT 1.15m / Capital Employed (Equity -283.1m + L.T.Debt 267.0m))
RoIC = 7.96% (NOPAT 910.9k / Invested Capital 11.4m)
WACC = 7.17% (E(6.87b)/V(8.05b) * Re(8.33%) + D(1.17b)/V(8.05b) * Rd(0.48%) * (1-Tc(0.21)))
Discount Rate = 8.33% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.11%
[DCF Debug] Terminal Value 80.49% ; FCFF base≈66.9m ; Y1≈63.3m ; Y5≈60.0m
Fair Price DCF = 7.85 (EV 1.27b - Net Debt 1.12b = Equity 153.4m / Shares 19.5m; r=7.17% [WACC]; 5y FCF grow -6.99% → 2.90% )
EPS Correlation: -38.04 | EPS CAGR: -18.65% | SUE: -0.52 | # QB: 0
Revenue Correlation: -8.32 | Revenue CAGR: -41.23% | SUE: -0.09 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.46 | Chg30d=-0.837 | Revisions Net=+1 | Analysts=4
EPS current Year (2026-06-30): EPS=-0.48 | Chg30d=+0.642 | Revisions Net=-2 | Growth EPS=+47.9% | Growth Revenue=-3.6%
EPS next Year (2027-06-30): EPS=-0.28 | Chg30d=-0.119 | Revisions Net=-1 | Growth EPS=+41.8% | Growth Revenue=+4.6%